Published Date: 26 Feb 2025
Multidrug resistance in cancer can be overcome by combining a drug that blocks a key enzyme with another anticancer drug, according to a study in preclinical models led by researchers at UT Southwestern Medical Center. The ...
Read Full NewsPatients with cancer who received mRNA-based COVID vaccines within 100 days of starting immune checkpoint therapy were twice as likely to be alive three years after beginning treatment, according to a new study led by researchers ...
Patients with advanced lung or skin cancer who received a COVID-19 mRNA vaccine within 100 days of starting immunotherapy drugs lived significantly longer than those who did not get the vaccine, researchers have found.
1.
novel approach to test the toxicity of cancer drugs.
2.
Photoacoustic spectral analysis for gaining knowledge of the tumor microenvironment.
3.
Adding Daratumumab to VRd Boosts MRD Negativity in Transplant-Ineligible Myeloma
4.
Make the Diagnosis: Can You Explain Her Rash and Conjunctival Injection?
5.
New First-Line Option for Advanced ALK-Positive Lung Cancer
1.
Exploring the Causes and Treatment of Granulocytopenia: A Comprehensive Guide
2.
Ultrasound: A Promising Tool in the Fight Against Malignant Breast Cancer
3.
Understanding the Importance of CA125: A Comprehensive Guide
4.
Exploring Digital Cognitive Stimulation for Elderly Breast Cancer Patients
5.
Mastering Modern Oncology: Accreditation, Education, and Research Trends for 2025
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Current Scenario of Blood Cancer- Further Discussion on Genomic Testing & Advancement in Diagnosis and Treatment
2.
An Eagles View - Evidence-based Discussion on Iron Deficiency Anemia- The Conclusion
3.
Experts' Opinion on the Goal of Treatment of Patients with Relapsed Adult B-cell ALL
4.
"Lorlatinib Upfront": A Niche but Powerful Option For ALK+ NSCLC
5.
Evolving Space of First-Line Treatment for Urothelial Carcinoma- Case Discussion
© Copyright 2025 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation